Talphera, Inc. (TLPH)

Market Cap	17.12M
Revenue (ttm)	651,000
Net Income (ttm)	-18.40M
Shares Out	16.97M
EPS (ttm)	-1.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,467
Open	1.020
Previous Close	1.030
Day's Range	0.980 - 1.020
52-Week Range	0.430 - 1.610
Beta	n/a
Analysts	Strong Buy
Price Target	6.00 (+512.25%)
Earnings Date	May 8, 2024

About TLPH

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (AR...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 14, 2011
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: TLPH

Analyst Forecast

According to one analyst, the rating for TLPH stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(512.25% upside)

Analyst Consensus: Strong Buy